Encouraging reductions in seizures and mortality were also seen in a mouse model of Dravet syndrome after ICV administration of ASO that increases expression of SCN1A transcripts by reducing non-productive splicing (Han et al., 2020). Here, SCN1A is linked to encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.